How do I buy Jazz Pharmaceuticals (JAZZ) stock?

Buying Jazz Pharmaceuticals (JAZZ) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "JAZZ", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy JAZZ by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for JAZZ on Gotrade?

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Jazz Pharmaceuticals from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Jazz Pharmaceuticals (JAZZ) pay dividends?

At the moment, Jazz Pharmaceuticals (JAZZ) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track JAZZ's performance via the price chart in the Gotrade app.

Is buying JAZZ on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy JAZZ?

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours. Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

How do I tell if JAZZ is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Jazz Pharmaceuticals (JAZZ) Stock Price Today & Analysis

% positive news of 10 articles

published over the past 14 days

Latest news

MarketBeat

Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

NeutralJAZZSeptember 20, 2026

MarketBeatNeutral

Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

JAZZ

MarketBeat

JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy

NeutralJAZZAugust 25, 2026

StocktwitsNeutral

JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy

JAZZ

CNBC

Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio

NeutralJAZZAugust 11, 2026

CNBCNeutral

Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio

JAZZ

About Jazz Pharmaceuticals

At Jazz Pharmaceuticals, our purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases — often with limited or no options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again.

SectorHealthcare

IndustryBiotechnology

Employees2,890

CEOMs. Renee D. Gala

IPO DateJun 1, 2007

HeadquartersDublin, Ireland

Key Executives

Name	Title	Year Born
Mr. Bruce C. Cozadd	Co-Founder & Chairman	1964
Ms. Renee D. Gala	President, CEO & Director	1972
Mr. Philip L. Johnson	Executive VP & CFO	1964
Ms. Neena M. Patil J.D.	Executive VP & Chief Legal Officer	1975
Dr. Robert Iannone M.D.	Executive VP, Chief Medical Officer and Global Head of Research & Development	1967
Ms. Samantha Pearce	Executive VP & Chief Commercial Officer	1966
Ms. Patricia Carr	Senior VP & Chief Accounting Officer	1971
Mr. John D. Bluth	Head of Investor Relations	1973
Ms. Heidi Manna	Executive VP & Chief People Officer	1971
Dr. Jed Black M.D.	Senior Vice President of Sleep & CNS Medicine	—

Fundamentals

Valuation

Market cap$15.45B

Price-to-sales ratio3.33

Price-to-book value3.19

Price-earnings ratio16.30

Return on Equity1.00%

Return on Sales-1.00%

Return on Assets0.00%

PEG ratio0.96

Earnings Per Share

Earnings Per Share$15.26

Income Statement

Average volume1,062,279

EBITDA$675.00M

1 year high (52w)$266.38

1 year low (52w)$125.79

Dividend

Ex dividend dateN/A

Dividend amount$0.00

Dividend yield0.00%

Last payment dateN/A

Dividend yield (TTM)N/A

Next earnings reportN/A

Solvency

Debt-to-equity ratioN/A

Technicals

OscillatorsSell5 Indicators

Moving AveragesStrong Sell12 Indicators

What the experts say

14 Wall Street Analyst Ratings

BUY

100% Buy

0% Hold

0% Sell

Target price

$298.86

Est return

25.48%

JP Morgan

Jessica Fye

Buy

Target price

$276.00

Est return

16.76%

Morgan Stanley

Jeffrey Hung

Buy

Target price

$322.00

Est return

36.22%

Goldman Sachs

Andrea Newkirk

Buy

Target price

$337.00

Est return

42.56%

Barclays

Etzer Darout

Buy

Target price

$271.00

Est return

14.64%

Deutsche Bank

David Hoang

Buy

Target price

$300.00

Est return

26.91%

Deutsche Bank

Gregg Gilbert

Buy

Target price

$270.00

Est return

14.22%

Piper Sandler

David Amsellem

Buy

Target price

$310.00

Est return

31.14%

Baird

Joel Beatty

Buy

Target price

$280.00

Est return

18.45%

Needham

Ami Fadia

Buy

Target price

$310.00

Est return

31.14%

Wells Fargo

Mohit Bansal

Buy

Target price

$300.00

Est return

26.91%

UBS

Ashwani Verma

Buy

Target price

$337.00

Est return

42.56%

Truist Securities

Gregory Renza

Buy

Target price

$281.00

Est return

18.87%

Canaccord Genuity

Gary Nachman

Buy

Target price

$290.00

Est return

22.68%

TD Cowen

Joseph Thome

Buy

Target price

$300.00

Est return

26.91%

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021									-1.1	+2.4	-11.8	+5.2
2022	+6.0	-2.4	+13.9	+0.8	-4.8	+5.7	-1.6	+2.8	-15.2	+6.2	+7.8	+1.8
2023	+0.2	-11.0	+4.1	-3.4	-9.3	-4.0	+5.1	+10.7	-10.0	-0.6	-7.2	+3.3
2024	-3.3	-3.9	+1.3	-6.9	-4.6	+0.9	+3.6	+1.4	+1.9	+0.9	+10.1	+1.3
2025	+0.5	+17.7	-11.5	-6.4	-7.8	-2.0	+4.7	+10.6	+1.7	+0.5	+27.6	-1.2
2026	-5.0	+13.6	-0.7	+7.8	+16.7	+3.6	+6.5	-0.4	-2.4

Jazz Pharmaceuticals (JAZZ) Stock

Fundamentals

Recent news

Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands

Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands

Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?

Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?

AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study

AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study

Technicals

Analyst Ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands

Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands

Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?

Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?

AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study

AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study

Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?

Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?

JAZZ Rises on Updated OS Results From Gastric Cancer Study

JAZZ Rises on Updated OS Results From Gastric Cancer Study

JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer

JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer

Jazz Pharmaceuticals Launches Ziihera After FDA Nod in HER2-Positive GEA

Jazz Pharmaceuticals Launches Ziihera After FDA Nod in HER2-Positive GEA

JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy

JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy

Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio

Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio

About Jazz Pharmaceuticals

Key Executives

Fundamentals

Valuation

Earnings Per Share

Income Statement

Dividend

Solvency

Technicals

What the experts say

Seasonality

FAQ

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade